Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1.

Hematologic malignancies such as acute and chronic myeloid leukemia are characterized by the malignant transformation of immature CD34(+) progenitor cells. Transformation is associated with elevated expression of the Wilm's tumor gene encoded transcription factor (WT1). Here we demonstrate that WT1 can serve as a target for cytotoxic T lymphocytes (CTL) with exquisite specificity for leukemic progenitor cells. HLA-A0201- restricted CTL specific for WT1 kill leukemia cell lines and inhibit colony formation by transformed CD34(+) progenitor cells isolated from patients with chronic myeloid leukemia (CML), whereas colony formation by normal CD34(+) progenitor cells is unaffected. Thus, the tissue-specific transcription factor WT1 is an ideal target for CTL-mediated purging of leukemic progenitor cells in vitro and for antigen-specific therapy of leukemia and other WT1-expressing malignancies in vivo.

[1]  J. Goldman,et al.  Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand. , 1999, Experimental hematology.

[2]  H. Stauss,et al.  Immunotherapy with CTLs restricted by nonself MHC. , 1999, Immunology today.

[3]  Anajane G. Smith,et al.  Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. , 1998, Blood.

[4]  M. Gavin,et al.  Minor histocompatibility antigens as targets for T-cell therapy after bone marrow transplantation. , 1998, Current opinion in hematology.

[5]  J. Melo,et al.  The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. , 1998, Blood.

[6]  J. Finke,et al.  Constitutive expression of the Wilms tumor suppressor gene (WT1) in renal cell carcinoma , 1998, International journal of cancer.

[7]  J. Dick,et al.  A newly discovered class of human hematopoietic cells with SCID-repopulating activity , 1998, Nature Medicine.

[8]  J. Falkenburg,et al.  T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[9]  J. Goldman,et al.  The kinetics and extent of engraftment of chronic myelogenous leukemia cells in non-obese diabetic/severe combined immunodeficiency mice reflect the phase of the donor's disease: an in vivo model of chronic myelogenous leukemia biology. , 1998, Blood.

[10]  Y. Oji,et al.  Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. , 1998, Blood.

[11]  J. Dick,et al.  High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. , 1998, Blood.

[12]  D. Roopenian,et al.  Much ado about minor histocompatibility antigens. , 1998, Immunology today.

[13]  U. Gullberg,et al.  Constitutive expression of the Wilms' tumor gene (WT1) in the leukemic cell line U937 blocks parts of the differentiation program , 1998, Oncogene.

[14]  J. Shabanowitz,et al.  The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. , 1998, Science.

[15]  H. Stauss,et al.  Generation of human tumor‐reactive cytotoxic T cells against peptides presented by non‐self HLA class I molecules , 1998, European journal of immunology.

[16]  A. Barrett,et al.  Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. , 1997, Blood.

[17]  T. Sugiyama,et al.  WT1 contributes to leukemogenesis: Expression patterns in 7,12‐dimethylbenz[a]anthracene (DMBA)‐induced leukemia , 1997, International journal of cancer.

[18]  U. Maurer,et al.  The Wilms' tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation in vitro. , 1997, Experimental Hematology.

[19]  C. Roberts,et al.  Altered expression of the WT1 wilms tumor suppressor gene in human breast cancer. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[21]  P. Baird,et al.  Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis. , 1997, Experimental hematology.

[22]  Y. Sonoda,et al.  Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. , 1997, Blood.

[23]  E. Sadovnikova,et al.  Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[24]  T. Kudoh,et al.  Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. , 1996, Blood.

[25]  P. Smith,et al.  A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines. , 1996, Oncogene.

[26]  J. Goldman,et al.  Current approaches to hematopoietic stem-cell purging in chronic myeloid leukemia. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  T. Akiyama,et al.  WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. , 1994, Blood.

[28]  E. Thiel,et al.  Expression of the WT1 Wilms' tumor gene by normal and malignant human melanocytes , 1994, International journal of cancer.

[29]  A. Tsukamoto,et al.  Human fetal bone marrow early progenitors for T, B, and myeloid cells are found exclusively in the population expressing high levels of CD34. , 1994, Blood.

[30]  A. Viel,et al.  Molecular mechanisms possibly affecting WT1 function in human ovarian tumors , 1994, International journal of cancer.

[31]  P. Parham,et al.  The HLA-A,B "negative" mutant cell line C1R expresses a novel HLA-B35 allele, which also has a point mutation in the translation initiation codon. , 1992, Journal of immunology.

[32]  J. Griffin,et al.  Clonogenic cells in acute myeloblastic leukemia. , 1986, Blood.

[33]  R. Demars,et al.  Homozygous deletions that simultaneously eliminate expressions of class I and class II antigens of EBV-transformed B-lymphoblastoid cells. I. Reduced proliferative responses of autologous and allogeneic T cells to mutant cells that have decreased expression of class II antigens. , 1984, Human immunology.

[34]  E. McCulloch.  Stem cells in normal and leukemic hemopoiesis (Henry Stratton Lecture, 1982) , 1983 .

[35]  A. Palumbo,et al.  Establishment of a Ph1-positive human cell line (BV173). , 1983, Journal of the National Cancer Institute.

[36]  C. Alvarado,et al.  Two new acute lymphoblastic leukemia cell lines with early B-cell phenotypes , 1982 .

[37]  C. Lozzio,et al.  Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. , 1975, Blood.

[38]  A. Jochemsen,et al.  The Wilms' tumor 1 gene: oncogene or tumor suppressor gene? , 1998, International review of cytology.

[39]  W. Wilmanns,et al.  Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. , 1990, Blood.

[40]  C. Alvarado,et al.  Two new acute lymphoblastic leukemia cell lines with early B-cell phenotypes. , 1982, Blood.